)
Medistim (MEDI) investor relations material
Medistim Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved record quarterly revenue of MNOK 201.7, up 11.1% year-over-year, with strong currency-neutral growth of 18.5%.
Own product sales grew 28.8% currency-neutral, with all regions contributing; Americas up 30.9%, EMEA up 11.5%, APAC up 57.5%, and China sales up 74.6%.
EBIT margin was 28.3% (EBIT MNOK 57.1), slightly lower than last year due to U.S. tariffs and sales mix.
Dividend of NOK 8 per share (MNOK 146.2) approved.
Direct sales operation established in Japan to strengthen APAC presence and capture distributor margin.
Financial highlights
Revenue: MNOK 201.7 (Q1 2026), up 11.1% year-over-year; currency-neutral growth at 18.5%.
EBIT: MNOK 57.1 (Q1 2026), EBIT margin 28.3%; EBITDA: MNOK 63.3, slightly below last year.
Gross margin: 79.6% (Q1 2026), impacted by APAC growth and U.S. tariffs.
Profit after tax: MNOK 40.3; EPS: NOK 2.20.
Cash position strong at MNOK 209.8; equity ratio 74.3%.
Outlook and guidance
Strong growth expected in APAC, especially China and Japan, with direct sales model enhancing margins.
Americas and U.S. expected to remain primary growth drivers.
Focus on expanding direct market coverage, flexible pricing, and growing vascular surgery segment.
Gross margin on own products expected to improve as direct sales increase.
Ongoing investments in R&D and IT infrastructure to support innovation and future growth.
- Record revenue and EBIT growth, strong cash, and NOK 8.00 dividend proposed for 2025.MEDI
Q4 202527 Feb 2026 - Growth to NOK 1 billion targeted via INTUI software, innovation, and global clinical validation.MEDI
CMD 20243 Feb 2026 - Record Q2 sales, margin recovery, and EMEA growth offset APAC headwinds.MEDI
Q2 20241 Feb 2026 - Q3 revenue up 7%, EBIT margin at 24%, strong Americas, and recurring sales at 73–75%.MEDI
Q3 202418 Jan 2026 - Record sales, stable profit, and new innovations set up for strong 2025 growth.MEDI
Q4 20241 Dec 2025 - Record Q1 with 35.7% revenue growth, 84.5% EBIT surge, and strong outlook as INTUI launches.MEDI
Q1 202526 Nov 2025 - Record H1 sales and profit growth, led by Americas, APAC, and new product launches.MEDI
Q2 202523 Nov 2025 - Record sales and EBIT growth, strong margins, and robust cash position amid global expansion.MEDI
Q3 202524 Oct 2025
Next Medistim earnings date
Next Medistim earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage